Anna Bal-Price

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3317862/publications.pdf

Version: 2024-02-01

20 papers	1,020 citations	687363 13 h-index	839539 18 g-index
20 all docs	20 docs citations	20 times ranked	1038 citing authors

#	Article	IF	Citations
1	Probabilistic modelling of developmental neurotoxicity based on a simplified adverse outcome pathway network. Computational Toxicology, 2022, 21, 100206.	3.3	15
2	Upscaling biological complexity to boost neuronal and oligodendroglia maturation and improve in vitro developmental neurotoxicity (DNT) evaluation. Reproductive Toxicology, 2022, , .	2.9	7
3	Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells. Reproductive Toxicology, 2022, 112, 36-50.	2.9	2
4	Exposure to human relevant mixtures of halogenated persistent organic pollutants (POPs) alters neurodevelopmental processes in human neural stem cells undergoing differentiation. Reproductive Toxicology, 2021, 100, 17-34.	2.9	31
5	The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays. Reproductive Toxicology, 2021, 103, 159-170.	2.9	22
6	Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures. Reproductive Toxicology, 2021, 105, 101-119.	2.9	19
7	Message from the Editor-in-Chief. Reproductive Toxicology, 2020, 91, E1.	2.9	0
8	Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells. Reproductive Toxicology, 2020, 98, 174-188.	2.9	15
9	Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept. Environmental Health, 2020, 19, 23.	4.0	61
10	Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes. Toxicology and Applied Pharmacology, 2018, 354, 3-6.	2.8	90
11	Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N -methyl- d -aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children. Toxicology and Applied Pharmacology, 2018, 354, 153-175.	2.8	47
12	Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 306-352.	1.5	121
13	Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods. Toxicology and Applied Pharmacology, 2018, 354, 7-18.	2.8	105
14	Editorial: Developmental neurotoxicity. Toxicology and Applied Pharmacology, 2018, 354, 1-2.	2.8	11
15	Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. NeuroToxicology, 2017, 59, 240-255.	3.0	69
16	Nrf2 pathway activation upon rotenone treatment in human iPSC-derived neural stem cells undergoing differentiation towards neurons and astrocytes. Neurochemistry International, 2017, 108, 457-471.	3.8	44
17	Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity. , 2017, 179, 84-95.		88
18	Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells. Neurochemistry International, 2017, 106, 62-73.	3.8	51

#	Article	IF	Citations
19	Putative adverse outcome pathways relevant to neurotoxicity. Critical Reviews in Toxicology, 2015, 45, 83-91.	3.9	92
20	International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. Archives of Toxicology, 2015, 89, 269-287.	4.2	130